^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy
Published date:
11/04/2021
Excerpt:
CONTRADICTING EVIDENCE: We used deep targeted sequencing for cancer-related mutations and Sanger sequencing for BCR::ABL1 on DNA samples from 167 subjects with CML...ASXL1 mutations with a VAF ≥ 17% and PHF6 mutations were associated with poor responses of the 3rd-generation TKI-therapy. STAT5A and RUNX1 mutations and high-risk ACAs were also associated with worse outcomes in persons receiving a 3rd-generation TKI.
DOI:
10.1182/blood-2021-150020
Source:
Title:
The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients
Published date:
11/01/2018
Excerpt:
Following the CCA/Ph- detection, somatic mutations were found in 30/52 (58%) patients (up to 4 per patient): ASXL1 (n=13)...6/8 patients with ASXL1 mutations in Ph-independent clones achieved MMR under first- or second-line TKI therapy.
DOI:
10.1182/blood-2018-99-112061
